Beacon Pharmaceutical Jupiter, LLC is developing a state-of-the-art, Smart LEED Platinum life science research and development complex in Palm Beach County, USA. This will be a private-public partnership with the city of Jupiter, Florida.
Upon completion, the project will house the Beacon Accelerator, a life sciences incubator, which will provide resident biotechnology companies with access to advanced R&D and cGMP manufacturing infrastructure resources for the production of existing and novel, clinical and commercial biologics (therapeutic protein-based humanized drugs).
We have two objectives:
To assist in the urgent need to develop the appropriate infrastructure to accelerate life sciences breakthroughs: Recent global events have highlighted the immediate and urgent need for US-centric biotechnology facilities, which can research, develop, manufacture, and ultimately, get new drugs and compounds rapidly and efficiently through the FDA approval process. The life sciences industry is evolving rapidly, and under increasing pressure to produce advanced therapeutics and vaccines targeting; Oncology, Central Nervous System-related diseases such as Alzheimer and Parkinson, ALS, Immunology, Cardiology, aging, rare and infectious diseases. The aim is to produce a diversified pipeline of preventative, regenerative, and disease-altering drugs in the US.
Jupiter complex will be a specialist building with a focus on life sciences businesses and the inhouse development of vaccines and therapeutics, an area of significant future growth in the ecosystem around Jupiter, across Florida and globally.
The LEED Platinum-certified smart building will be built by with the expertise of DPR Construction, a leading nationwide technical builder that specializes in complex and sustainable projects with a strong focus on life sciences. The Project will be erected on a 9-acre parcel of land belonging to the Town of Jupiter, for which a 99-year lease has been negotiated with the Town. The lease provides PropCo with a self-amortizing call option to buy the land at any point within the first 30 years.
The building will comprise approximately 160,000 square feet. The use of the building will be as follows:
90,000 square feet of offices, wet laboratories, library, auditorium, amenities for academic and life science conferences and a Contract Research Organization. The area could physically host up to 70 life sciences companies which are further referred to as the Accelerator Partner Companies.
70,000 square feet for a Bioflex CRO and Disposable Equipment Biologics cGMP manufacturing facility, which will allow our companies to benefit from a one-stop solution to manage the process of developing drugs from IP discovery to commercialization without the need for relocation.
The Bioflex space will be operated by a major international Contract Development Manufacturing Organization which will enter into a 20-year triple net lease agreement